Altay Therapeutics YC Başvurusu

Winter 2020Active

Altay Therapeutics, Healthcare şirketi olarak Winter 2020 grubunda Y Combinator'dan geçti. Aşağıda: şirketin ne yaptığı, kimin kurduğu ve gerçek YC formunda yeniden yapılandırılmış YC başvurusu.

YC grubu: Winter 2020
Sektör: HealthcareTherapeutics
Ekip büyüklüğü: 6
Durum: Active
Lansmanı Yapıldı: 2020

Kurucular

Ali OzesFounder
Osman OzesFounder

Altay Therapeutics ne yapar

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Altay Therapeutics'in YC başvurusu, yeniden yapılandırılmış

Y Combinator başvurusu

Altay Therapeutics, Winter 2020 dönemi. Gerçek form soruları, herkese açık verilerden yanıtlandı.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

Tam başvuruda 21 ek cevap

Founders, Progress, Idea, Equity, Curious, Batch Preference tam sürümde. YC Insights'ta, diğer her YC grubu yanında açmak için ücretsiz bir hesap oluşturun.

Tüm başvuruyu gör

Sıkça Sorulan Sorular

Bu, Altay Therapeutics şirketinin gerçek YC başvurusu mu?

Hayır. Y Combinator gönderilen başvuruları gizli tutar. Bu bir yeniden yapılandırmadır: gerçek YC form soruları, Altay Therapeutics'in kamuya açık verilerinden (lansman notları, kurucu geçmişleri, ürün açıklaması) yanıtlanmıştır. Altay Therapeutics gibi bir şirketin YC'ye kendisini nasıl sunacağını gösterir, gönderdikleri metni değil.